Menu
← Oncology Approval Tracker
FDA DECISION ·
Tudriqev + nivolumab
vusolimogene oderparepvec-wtpg with nivolumab · Replimune
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1 antibody-based regimen.
LAMPGEN ANALYSIS
Why it matters
The approval adds an intratumoral oncolytic virus combination after PD-1 therapy. Separate response in the efficacy-evaluable subgroup from results across all trial participants.
What research teams should watch
Track injected and noninjected lesions, handling procedures and multidisciplinary injection capacity. Verify the confirmatory trial design before discussing comparative benefit.
PRIMARY RECORDS